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Summary 
 
 
 
 
1-Phenyl-2-(pyrrolidin-1-yl)pentan-1-one (α-PVP) is a psychomotor stimulant that has originally 
been explored in the 1960s. It is the desmethyl analogue of pyrovalerone, which is listed in 
Schedule IV of the 1971 United Nations Convention on Psychotropic Substances. A closely 
related derivative of α-PVP gives rise to 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one 
(3,4-methylenedioxypyrovalerone, MDPV) that has recently been placed in Schedule II of the UN 
Convention on Psychotropic Substances (1971). The first official notification of α-PVP detection 
in the European Union was received in February 2011. 
 
α-PVP is a synthetic cathinone derivative and commonly referred to as a new psychoactive 
substance (NPS), ‘research chemical’, ‘bath salt’ or ‘designer drug’. α-PVP appears to act as a 
potent blocker at the dopamine and norepinephrine transporter and pre-clinical research into areas 
of abuse liability, psychomotor activity and drug discrimination suggests that the properties of α-
PVP are reminiscent of MDPV, methamphetamine and cocaine.   
 
Data indicate that α-PVP is most commonly encountered in powdered and tablet form. In addition 
to being available from Internet vendors in both wholesale and consumer amounts, α-PVP has also 
been encountered in products destined for the traditional illicit drugs market, for example, in form 
of ‘ecstasy’ tablets.  
 
More than 130 deaths have been associated with α-PVP and among the non-fatal acute 
intoxications reported, hospitalizations were required. In cases where α-PVP use was established 
unambiguously, neurological and cardiovascular effects consistent with an extensive 
psychostimulant toxidrome have been observed and included cardiotoxicity, violent behavior and 
display of psychotic behavior. In addition to use by traditional recreational drug users it appears 
that α-PVP is also used by high-risk drug users including those who inject. 
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1.   Substance identification  
A. International Nonproprietary Name (INN) 
Not applicable. 
B. Chemical Abstract Service (CAS) Registry Number 
14530-33-7 (free base) 
5485-65-4 (hydrochloride salt) 
14859-27-9 (tartrate salt) 
14859-28-0 (maleate salt)  
14995-79-0 (citrate salt) 
100175-06-2 (hydrogen maleate salt) 
16121-74-7 (sulfate salt) 
13415-49-1 (sulfate salt, 1:1) 
1346599-00-5 (d8-free base) 
1781744-06-6 (d8-hydrochloride salt) 
C. Other Names 
α-Pyrrolidinopentiophenone, α-pyrrolidinovalerophenone, α-PVP, alpha-PVP, 
desmethyl pyrovalerone, prolintanone, β-keto-prolintane, pyrodilyl ketone, α-
pyrrolidino ketone, 2-(1-pyrrolidinyl)-valerophenone, 2-pyrrolidinovalerophenone, 
2-(1-pyrrolidinyl)-valerophenone, 2-(pyrrolidin-1-yl)phenylpentan-1-one, 2-
pyrrolidin-1-yl-1-phenylpentan-1-one,  O-2387. 
D. Trade Names 
Not applicable. 
E. Street Names 
Street names encountered in European Member States and reported to the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
1
 include ‘grind’, 
‘flakka’, ‘gravel’, ‘crystal love’, ‘Pure NRG’, ‘Snow Blow’ and ‘vanilla sky’. 
Prominent street names encountered in the United States of America include 
‘flakka’ and ‘gravel’. Product names reported to contain α-PVP include ‘Yayo soft’, 
‘Yayo experimental’ and ‘1NRG’ (Belgium); ‘Ocean Breath’ (Cyprus); ‘Guarana 
Coco jumbo’, ‘Cherry Coco jumbo’, ‘ILOVEPARADE’ and ‘SENSATION’ 
(Czech Republic); ‘NRG3’, ‘Energy 3’ and ‘PV-11’ (France); ‘Pure NRG’ 
(Germany); ‘A-1 PUP’ (Italy); ‘E21’, ‘G-Y’, ‘S1 Turbo’ and ‘GIE-ES M’ (Poland); 
‘Sextacy’, ‘Bloom’, ‘Quick Silver’, ‘Formula 3’, ‘Ivory’ and ‘Vanila Sky’ 
(Portugal); ‘Doves’, ‘Fire Ball’, ‘Green Speed’, ’Knock out’, ‘Max’, ‘Speedway’, 
‘Total speed’ and ‘Ultra Violet Exclusive’ (Slovakia); and ‘NRG-3’, ‘Energy - 3 
(NRG-3)’ and ‘Spellweaver’ (United Kingdom).  
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F. Physical properties 
α-PVP HCl is a white crystalline powder. 
 
G. WHO Review History 
α-PVP was not previously pre-reviewed or critically reviewed. Preliminary data 
collected from literature and different countries indicated that this substance may 
cause substantial harm and that it has no medical use.
1
 
2. Chemistry 
A. Chemical Name 
IUPAC Name: 1-Phenyl-2-(pyrrolidin-1-yl)pentan-1-one 
 
CA Index Name: 1-Phenyl-2-(1-pyrrolidinyl)-1-pentanone 
B. Chemical Structure 
Free base: 
    
    
   Note: Asterisk (*) refers to a chiral center 
 
Molecular Formula: C15H21NO (free base) 
Molecular Weight: 231.34 g/mol 
Melting point: 
Hydrochloride salt: 173 °C (ethanol/diethyl ether)
2, 3
 
Hydrochloride salt: 162 °C
4, 5
  
Hydrochloride salt: 162 °C (acetone)
6
 
Hydrochloride salt: 104–106 °C followed by 169–170 °C (anhydrous)7 
Acid sulfate salt: 140 °C (isopropanol)
6
 
Tartrate salt: 148–149 °C4 
Tartrate salt: 148–149 °C (isopropanol)6 
Maleate salt: 131 °C
4
 
Maleate salt: 131 °C (acetone)
6
 
Hydrogen maleate salt: 131 °C
5
 
Hydrogen maleate salt: 131 °C (acetone)
6
 
Citrate salt: 88 °C
4
 
Citrate salt: 88 °C (acetone)
6
 
 
Boiling point:  
Free base: 113 °C 
4-6
 
N
CH3
O
*
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C. Stereoisomers  
The presence of a chiral center at the α-carbon of the side chain gives rise to the 
enantiomeric pair of (S)-α-PVP and (R)-α-PVP, respectively. Currently, it appears 
that data about potentially distinguishable pharmacological properties have not been 
published. α-PVP is most likely to be available as the racemic mixture. 
D. Synthesis 
Methods of manufacturing: 
One of the main procedures used for α-PVP synthesis includes the α-halogenation 
(e.g. using bromine) (step i) of the 1-phenylpentan-1-one (valerophenone) precursor 
(a) and formation of the 2-bromo-1-phenylpentan-1-one (b). Reaction with 
pyrrolidine (step ii) gives α-PVP (c) that can then be converted into a range of salts. 
Valerophenone (a) may also been obtained from a number of precursors including 
benzene or benzaldehyde. One of several alternatives may include the oxidation of 
the ephedrine-type 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-ol precursor
7-9
 or reaction 
of 2-bromo-1-phenylpentan-1-one with alkoxide reagents to yield epoxide 
intermediates that can then be reacted with pyrrolidine.
8, 10, 11
A Grignard reaction 
between phenylmagnesium halide with 2-(pyrrolidin-1-yl)pentanamide has also 
been suggested.
8
 
 
 
 
 
 
E. Chemical description 
α-PVP is the desmethyl analogue of pyrovalerone, which is listed in Schedule IV of 
the 1971 United Nations Convention on Psychotropic Substances. A closely related 
derivative of α-PVP is 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one 
(3,4-methylenedioxypyrovalerone, MDPV), a cathinone derivative that was subject 
to a critical review during the thirty-sixth meeting of the Expert Committee on Drug 
Dependence in 2014. The Committee recommended that MDPV be placed in 
Schedule II of the 1971 Convention.  
F. Chemical properties 
α-PVP hydrochloride is a white, crystalline powder. Its solubility was given as ~10 
mg/mL in PBS (pH 7.2); ~20 mg/mL in EtOH; ~10 mg/mL in DMSO and ~3 
mg/mL in DMF, respectively.
12
 
N
CH3
OO
CH3
O
CH3
Br
i ii
(a) (b) (c)
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G. Chemical identification 
The first thermal properties have been described in the early 1960s (Section B). The 
first NMR data have been published in 2005 and 2006, which followed a systematic 
investigation of pyrovalerone analogues that included the evaluation of monoamine 
transporter activities.
2, 3
 Although α-PVP was reported to have been encountered in 
a German seizure in 2005,
13
 mass spectral data derived from metabolism studies 
were only published in 2009.
14
 Implementation of the Marquis test was reported to 
result in a ‘clear’ reaction whereas formation of a ‘gray/black’ result was obtained 
from the Mecke test.
15
 α-PVP has been thoroughly employed for analytical 
purposes and featured in a range of routine methods of analysis associated with 
forensic and clinical investigations (Table 1). 
 
Table 1. Representative examples of scientific literature associated with chemical analysis and α-PVP 
Techniques 
a
 Comment Reference 
GC-MS Metabolism studies in-vivo (male Wistar rats) and in-vitro. Sauer et al.
14
 
NMR, GC-MS, FTIR,  Characterization of synthesized material. Casale and Hays
16
 
ESI-in-source CID-MS Characterization of synthesized material. Power et al.
17
 
LC-TOF-MS Analysis of branded products. Shanks et al.
18
 
LC-QqQ-MS/MS Method development for oral fluid analysis and application to test 
samples obtained from subjects. 
Amaratunga et al.
19
 
LC-Q-MS/MS Method development for urine analysis and application to authentic 
urine specimens. 
Concheiro et al.
20
 
LC-MS/MS Detection in biofluids and powdered sample by FTIR and GC-MS. Eiden et al.
21
 
GC-MS Analysis of a branded product. Elie et al.
22
 
LC-QqQ-MS/MS Detection in biofluids. Marinetti et al.
23
 
LC-Q-MS Method development for hair analysis and application to authentic 
hair specimens. 
Namera et al.
24
 
GC-MS, LC-Q-MS Detection in biofluids. Namera et al.
25
 
GC-MS Detection in biofluids. Saito et al.
26
 
LC-MS/MS Detection in biofluids. Shanks et al.
27
 
GC-MS Characterization of synthesized material. Tsujikawa et al.
28
 
LC-Q-TOF-MS/MS Metabolism studies in-silico and in-vitro and application to authentic 
urine specimens. 
Tyrkkö et al.
29
 
LC-Q-TOF-MS/MS Characterization of supplied standards. Fornal
30
 
GC-MS, LC-QqQ-MS/MS Detection in biofluids. Hasegawa et al.
31
 
LC-TOF-MS Detection in biofluids. Knoy et al.
32
 
GC-MS, LC, ion trap-
Orbitrap-MS/MS 
Analysis of branded products. Leffler et al.
33
 
MALDI-TOF-MS and Q-
TOF-MS/MS 
Method development for blood and application to authentic blood 
specimens. 
Minakata et al.
34
 
GC-MS Detection in authentic urine specimens. Namera et al.
35
 
LC-TOF-MS Analysis of products purchased from shops. Schneir et al.
36
 
GC-MS, LC-QqQ-LIT-
MS/MS 
Detection in authentic urine specimens. Shima et al.
37
 
LC-UV Chiral analysis of products obtained from Internet retailers. Taschwer et al.
38
 
13
C-NMR Analysis of reference material. Uchiyama et al.
39
 
GC-MS Detection in authentic urine specimens. Uralets et al.
40
 
LC-QqQ-MS/MS Use as internal standard for analyses of biofluids. Wurita et al.
41
 
GC-MS, LC-UV, FTIR, IMS Characterization of supplied samples. Armenta et al.
42
 
LC-QqQ-MS/MS Detection in wastewater samples. Borova et al.
43
 
LC-Q-Orbitrap-MS/MS Method development for urine analysis and application to authentic 
urine specimens. 
Concheiro et al.
44
 
Several GC-MS and LC-MS Metabolism studies in-vitro and application to authentic biofluids Friscia et al.
45
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based methods. samples 
SPME-GC-MS Method development using supplied samples. Fujii et al.
46
 
FTIR, NMR Characterization of synthesized samples Guha et al.
9
 
LC-Q-TOF-MS/MS In-vitro metabolism studies. Negreira et al.
47
 
GC-MS. LC-Q-MS Detection in biofluids and powdered material. Sykutera et al.
48
 
LC-QqQ-MS/MS Detection in biofluids. Yap and Drummer
49
 
a 
GC: gas chromatography; MS: mass spectrometry: MS/MS: tandem mass spectrometry; ESI: electrospray ionization; 
MALDI: matrix-assisted laser desorption/ionization; CID: collision-induced dissociation; TOF: time-of-flight; Q: quadrupole; 
QqQ: triple quadrupole; LIT: linear ion trap; LC: liquid chromatography (various forms); NMR: nuclear magnetic resonance 
spectroscopy; FTIR: Fourier transform infrared; UV: ultraviolet; SPME: solid-phase microextraction. 
 
3. Ease of convertibility into controlled substances 
 
No information available. 
4. General pharmacology 
 
One of the prominent features frequently encountered with cocaine and amphetamine-like 
psychostimulants includes the ability to increase extracellular levels of dopamine (DA), 
norepinephrine (noradrenaline, NE) and serotonin (5-HT), respectively. An important 
question related to the evaluation of psychostimulant properties on the molecular level 
includes the assessment of drug action at the dopamine (DAT), norepinephrine (NET) and 
serotonin (SERT) transporters. Evidence is mounting that α-PVP is potent blocker at DAT 
and NET with significantly reduced activity at SERT. So far, insights gained from 
investigations carried out in vivo also indicate the propensity of α-PVP to behave as a 
psychostimulant with potential for abuse liability under conditions explored in animal 
studies. It is anticipated that further studies will come to light given the emergence of this 
substance in recent years. Data obtained from systematic clinical studies in humans are 
currently unavailable.  
A. Pharmacodynamics 
The central nervous system stimulant and hypertensive properties of α-PVP and 
closely related ‘α-pyrrolidino-valerophenones’ have been recognized during earlier 
pharmaceutical explorations in the 1960s which led to a variety of suggested drug 
formulations (Section 4B).  
 
In-vitro pharmacology 
The first indication that α-PVP acted as a catecholamine-selective reuptake inhibitor 
appeared in the mid-2000s and was published by Meltzer et al. as part of 
comprehensive investigations on 38 analogues of pyrovalerone.
2,3
 Indeed, more 
recent studies confirmed that the profile of α-PVP was consistent with DA and NE 
uptake blockage rather than substrate-type release, thus, behaving cocaine and 
MDPV-like rather than amphetamine-like.
50-53
 Key data are summarized in Table 2 
and it can be seen that transporter selectivity of α-PVP was comparable to MDPV 
as indicated as well by similar DAT/SERT ratios (α-PVP > 781; MDPV = 806). In 
comparison, non-selectivity of cocaine resulted in a DAT/SERT of 1.5 instead as 
shown, for example, by Marusich et al.
51
 Radioligand binding data reported at this 
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stage (Table 2) indicate that α-PVP may show affinity in the micromolar range 
where highest affinity was observed at the 5-HT1A receptor (Ki = 5.2 μM using 
[
3
H]-8-OH-DPAT and indatraline). In contrast, Ki values determined for DAT and 
NET were 0.007 μM and 0.06 μM, respectively.53 The extent to which these lower 
affinities might impact on the psychoactive properties of α-PVP in humans is 
unclear but may become relevant depending on dosage levels.  
 
Table 2. In vitro assay data for α-PVP  
Uptake 
a 
Affinity 
b 
Ref 
DAT 
IC50/nM 
NET  
IC50/nM 
SERT  
IC50/nM 
DAT  
Ki/nM 
NET  
Ki/nM 
SERT  
Ki/nM 
 
52.3 
 
56.0 
 
-- 33.7 
 
199 
 
> 10,000 
 
Madras et al.
2
; Meltzer et al.
 c,3
 
205 
d
 -- -- -- -- -- Kolanos et al.
 e,50
 
12.8 14.2 > 10,000 -- -- -- Marusich et al.
 f,51
 
17.5 -- > 10,000 -- -- -- Kolanos et al.
52 
 
40 20 > 100,000 7 60 > 30,000 Rickli et al.
 g,53
 
Additional in-vitro assay data for α-PVP 
Receptor binding profiles: 
h
  
Ki (µM): 5-HT1A = 5.2; 5-HT2A > 13; 5-HT2C > 13; α1A > 15; α2A >20; D1 > 12; D2 > 
10; D3 > 17; H1 > 13; TA1rat = 16.3; TA1mouse > 20; TA1human > 20.   
5-HT2B Activation potency (EC50):
 i
 > 20 µM and no activation. 
Cytotoxicity: None detected under conditions used (at 100 µM).
 j 
 
Rickli et al.
g,53
 
a
 Ref 
3
: HEK293-hDAT, HEK293-hNET, HEK293-hSERT ([
3
H]DA, [
3
H]NE, [
3
H]5-HT); Ref 
50
: HEK-hDAT ([
3
H]DA); 
Ref 
51
: rat brain synaptosomes (5 nM [
3
H]DA, [
3
H]NE, [
3
H]5-HT); Ref 
52
: rat brain synaptosomes (5 nM [
3
H]DA, [
3
H]5-
HT); Ref 
53
: HEK293-hDAT, HEK293-hNET, HEK293-hSERT (5 nM [
3
H]DA, [
3
H]NE, [
3
H]5-HT)  
b
 Ref 
3
: HEK293-hDAT, HEK293-hNET, HEK293-hSERT ([
125
I]RTI-55, 40-80 pM)); Ref 
53
: HEK293-hDAT, HEK293-
hNET, HEK293-hSERT (N-methyl-[
3
H]-nisoxetine and indatraline (NET), [
3
H]citalopram and indatraline (SERT), 
[
3
H]WIN35,428 and indatraline (DAT); A ‘DAT affinity’ value of 13 nM was also given in ref. 2 
c
 Uptake data cocaine
3
 (IC50/nM): DAT = 461; NET = 378; SERT = 494. Affinity data for cocaine
3
 (Ki/nM): DAT = 432; 
NET = 2,150; SERT = 358. 
d
 Additional experiments (two-electrode voltage clamp; -60 mV) using Xenopus oocytes expressing hDAT to illustrate 
inhibitor-like behaviour. Following α-PVP exposure (10 μM), DA (5 μM) elicited hDAT-mediated inward current 25.4% 
relative to amplitude obtained from first DA application (5 μM).  
e 
Affinity data for MDPV
50
: DAT Ki = 135 nM.  
f
 Uptake data MDPV
51
 (IC50/nM): DAT = 4.1; NET = 25.9; SERT > 10,000. Uptake data cocaine
51
 (IC50/nM): DAT = 211; 
NET = 292; SERT = 313. Uptake data amphetamine
51
 (IC50/nM): DAT = 93; NET = 67; SERT = 3,418.  
g
 Uptake data MDPV
53
 (IC50/nM): DAT = 50; NET = 40; SERT = 9,600. Uptake data methamphetamine
53
 (IC50/nM): DAT 
= 1,100; NET = 140; SERT = 18,000. Uptake data amphetamine
53
 (IC50/nM): DAT = 1,300; NET = 70; SERT = 35,000. 
Affinity data for MDPV
53
 (Ki/nM): DAT = 10; NET = 8; SERT = 2,900. Affinity data for methamphetamine
53
 (Ki/nM): 
DAT = 1,800; NET = 3,000; SERT = 24,600. Affinity data for amphetamine
53
 (Ki/nM): DAT = 5,700; NET = 1,000; SERT 
> 25,000. 
h
 [
3
H]-8-OH-DPAT and indatraline (5-HT1A), [
3
H]ketanserin and spiperone (5-HT2A), [
3
H]mesulergine and mianserin (5-
HT2C), [
3
H]prazosin and risperidone (α1 adrenergic receptor), [3H]rauwolscine and phentolamine (α2 adrenergic receptor), 
[
3
H]SCH 23390 and butaclamol (DAD1), [
3
H]spiperone and spiperone (DAD2 and DAD3), [
3
H]pyrilamine and clozapine (H1) 
and [
3
H]-RO5166017 and RO5166017 (TA1).  
i
 HEK293-h5-HT2B and FLIPR assay. 
j
 ToxiLight BioAssay (measurement of adenylate kinase release from damaged cells). 
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In-vivo pharmacology 
The first indication that α-PVP interacted with the dopamine transporter in the 
animal brain came from Madras et al. who confirmed displacement of the high 
affinity probe [
11
C]WIN 35,428 by positron emission tomography in rhesus 
monkeys. The occupancy was given as 64%.
2
 Additional studies published since 
2014 provided further evidence that effects induced by α-PVP might have been 
comparable to those induced by MDPV, cocaine and methamphetamine (Table 3), 
such as locomotor stimulation
51, 54-56
 and elevation of extracellular dopamine levels 
in the striatum of 8 weeks old Balb/c male mice following microdialysis studies.
54
 
α-PVP also resulted in full substitution for the discriminative stimulus effects of 
cocaine and methamphetamine
56,57
 and was shown to decrease intracranial self-
stimulation thresholds in male Sprague-Dawley rats.
58
 Conditioned place preference 
was observed at some doses
56
 (Table 3) and both α-PVP and MDPV were 
determined to show similar potency and efficacy under a progressive-ratio schedule 
of reinforcement.
55
 Consistent with the ability of a range of psychomotor stimulants 
to mediate hyperactive behavior via increased dopamine transmission, 
implementation of dopamine D1 and D2 receptors antagonism experiments resulted 
in attenuation of locomotor activation.
51, 54
 Bizarre behavior and stereotypy have 
been observed in several studies, especially at higher dosage levels.    
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Table 3. In vivo assay data for α-PVP 
Behaviour Neurochemistry / Physiology etc.  Ref 
 
-- Dopamine transporter (DAT) occupancy 
(rhesus monkeys):
 a
  
64% as determined by positron emission 
tomography imaging; intravenous injection 
following pre-treatment with [
11
C]WIN 
35,428 ([
11
C]CFT).  
Madras et al.
2
 
Locomotor activity: 
b  
Oral administration of α-PVP (25 mg/kg) and 
methamphetamine (5 mg/kg) as a positive control. 
Earlier and more pronounced onset observed with 
α-PVP (10 min) and considered “stronger”; effects 
also considered “more profound” than those 
observed for methamphetamine. Both substances 
displayed significant increases in locomotor 
activity based on distance travelled in metres. 
Administration of D1 and a D2 receptor antagonists 
before α-PVP treatment led to attenuated distance 
travelled. Mean reduction (0−30 min) to 43% (D1) 
and 54% (D2); attenuation also observed in the 
30−60 min time slot although less pronounced.  
 
Microdialysis (striatum):
 c  
Oral administration of α-PVP (25 mg/kg) 
and methamphetamine (5 mg/kg) led to 
significant increase in dopamine levels in 
dialysate samples. α-PVP showed shorter 
onset than methamphetamine but less 
pronounced concentration levels, e.g. 
~600% DA increase for methamphetamine 
vs. ~ 350% DA increase at 20 min post-
administration).  
 
Kaizaki et al.
54
 
Locomotor activity:
 d
  
Significant increases in activity over entire 60 min 
session at 3.0−10.0 mg/kg) and 20−50 min at 1 
mg/kg following α-PVP injection. Increases of 
cumulative beam breaks considered significant at 
3.0 and 10 mg/kg. Administration of D1 receptor 
antagonist before α-PVP treatment led to 
significant reduction in total beam breaks with a 
main effect of pre-treatment at 3.0 mg/kg α-PVP. 
Doses needed to significantly increase locomotor 
activity during the first 10-min bin were lower 
than those for cocaine.  Pre-treatment with D1 
receptor antagonist attenuated locomotor activity.  
 
Functional observational battery (FOB): 
d 
Significant increases in some observational 
measures consistent with psychomotor stimulant 
properties (ranging between 3−10 mg/kg and 
10−17 mg/kg): locomotion (first 10 min), 
exploration, circular ambulations, flattened body 
posture, hyperactivity, stereotyped head weaving, 
stereotyped head circling and stimulation. No 
significant increased noted for ataxia, retropulsion, 
bizarre behaviour and grooming.  
-- Marusich et al.
51
 
Intracranial self-stimulation (ICSS) thresholds:
 e
 
Significant ICSS threshold reductions at 0.3 and 1 
mg/kg (~19%) doses and comparable to 
methamphetamine. ED50: α-PVP = 0.35 mg/kg; 
methamphetamine = 0.2 mg/kg); at 5 mg/kg (or 3 
mg/kg for methamphetamine) aversive effects 
observed and increase of ICSS thresholds. 
-- Watterson et al.
58
 
Locomotor activity: 
f  
Peak locomotor responses observed at 1.0 mg/kg 
and lasted ~2 h. Locomotor stimulant effects very 
similar to MDPV; α-PVP showed rebound of 
 
Thermoregulation: 
f
  
Modest, but consistent; dose-dependent 
hypothermic alteration ~0.75 °C up to 3 
Aarde et al.
55
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activity 2 h after injection of 5.6 mg/kg dose.   
 
Intravenous self-administration:
 f
  
α-PVP considered similar to MDPV in potency 
and efficacy as a reinforcer; intake and lever 
discrimination of α-PVP higher than MDPV. 
hours after dosing.  
Locomotor activity: 
g 
Time- and dose-dependent effects from 2.5 to 25 
mg/kg; stimulant effects with 2.5, 5, and 10 mg/kg 
observed within 10 min lasting 240–290 min. 
Stimulant effects not observed in the first 60 min 
at 25 mg/kg and lasted 280 min.  
 
Drug discrimination:
 h 
Full substitution for discriminative stimulus 
effects of cocaine and methamphetamine; slope of 
α-PVP dose effect in cocaine-trained rats 
substantially shallower than dose-effect curve 
determined for methamphetamine-trained animals. 
 
Conditioned place preference (CPP): 
i 
CPP was produced (0.3−10 mg/kg) with U-shaped 
dose−effect curve, i.e. no CPP at high (30 mg/kg) 
and low doses (0.1 mg/kg).   
-- 
 
 
 
 
Gatch et al.
56
 
Drug discrimination:
 j 
Full substitution of observed; total drug-lever 
responses reached 88.6% at 2.0 mg/kg; potency 
differences expressed as ED50 values: 
methamphetamine = 0.3 mg/kg; α-PVP = 0.7 
mg/kg; cocaine = 3.3 mg/kg; control response 
rates were significantly reduced at does of 1.0 
mg/kg (methamphetamine), 2.0 mg/kg (α-PVP) 
and 8.0 mg/kg (cocaine).  
 Naylor et al.
57
 
a 
Comparison of positron emission tomography imaging pre- and post-drug session based on reduced [
11
C]WIN 35,428 
binding one hour or longer after administration. 
 
b
 Balb/c male mice (8 weeks old) and comparison with saline. Locomotor activity measured for 120 min after administration 
using a video tracking system. Antagonism experiment: D1 receptor antagonist (+)-SCH23390 (50 μg/kg, i.p.), D2 receptor 
antagonist sulpiride (50 mg/kg, i.m.); antagonists administered 30 min before α-PVP (25 mg/kg) treatment. Locomotor 
activity measured for 60 min.  
c
 Balb/c male mice (8 weeks old). Extracellular dopamine levels determined in dialysate and collected for 120 min (12 
measurements) following oral administration of α-PVP (25 mg/kg), methamphetamine (5 mg/kg) or water (10 ml/kg).   
d
 Locomotor activity studies: male ICR mice; monitoring horizontal movements (two 4-beam infrared arrays) / beam breaks 
for 60 min following α-PVP administration (1, 3 and 10 mg/kg, i.p.); D1 receptor antagonist (+)-SCH23390 (30 μg/kg, s.c.) 
given 30 min before drug administration; FOB studies: Male ICR mice.   
e
 Male Sprague-Dawley rats, unilaterally implanted stainless steel bipolar electrode into medial forebrain bundle; α-PVP in 
comparison with methamphetamine (both 0.1, 0.3, 1, and 3 mg/kg; i.p.); training: nose-poke responses on FR1 schedule.  
f
 Male Wistar rats; fixed-ratio 1 dose-response testing (1 h) (trained on 0.1 mg/kg/infusion) and progressive-ratio (3 h), dose-
response testing (dose-response: 0.018–0.56 mg/kg/infusion); activity rate determined by radiotelemetry transmitters for 180 
min following α-PVP administration (1, 5.6 and 10 mg/kg, i.p.). Thermoregulation: room conditions 21 °C, single housing.  
g
 Male Swiss Webster mice in temperature environment of 22−24 °C; panel of 16 infrared beams;  α-PVP doses 1, 2.5, 5, 10 
and 25 mg/kg (i.p.); horizontal activity measured for 8 h. 
h
 Male Sprague-Dawley rats; α-PVP doses 0.1, 0.25, 0.5, 1, 2.5, 5 and 10 mg/kg (i.p.); rats trained to discriminate cocaine 
(10 mg/kg, i.p.) or methamphetamine (1 mg/kg i.p.) from vehicle (saline) using two-lever choice methodology.  
i
 Male Swiss Webster mice; α-PVP place conditioning doses of 0.1, 0.3, 1, 3, 10, 30 mg/kg (i.p.).   
j
 Male Sprague-Dawley rats; trained to discriminate methamphetamine (1.0 mg/kg) from saline using fixed-ratio (FR) 20 
schedule; ; α-PVP doses 0.25–2.0 mg/kg (i.p.); cocaine (1.0–8.0 mg/kg) used as positive control. 
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B.  Routes of administration and dosage 
A number of drug formulations related to α-PVP have been suggested and 
published in the earlier patent literature and are summarized in Table 4. The claims 
made referred to its use as central nervous stimulants and hypertensive agents in 
humans. α-PVP, together with its para-substituted analogues (including chloro-, 
methyl- and methoxy-) was claimed to show ‘good central-stimulating action 
without undesirable effects, such as circulatory effects’.8  
 
Table 4. Suggested formulations encountered in the patent literature 
a
 
Formulation Dosage unit Ref 
Tablets (240 mg, ø = 9 mm) Production: 110 g product in 2606 g composition for 
tableting; suggested range 5 – 60 mg  
8
 
Suppository 10 – 60 mg 8 
Tablets (220 mg, ø = 9 mm) 20 mg  
6
 
Dragees (350 mg, ø = 9 mm, 
convex) 
30 mg 
6
 
Ampoules (2 mL) 10 mg 
6
 
Drops (1 mL) 15 mg 
6
 
Tablets (220 mg) 20 mg  
4, 5
 
Coated pills (~350 mg) 30 mg 
4, 5
 
Ampoules (2 mL) 10 mg 
4, 5
 
Drops (1 mL) 15 mg 
4, 5
 
a
 Patents also capture several other para-ring-substituted analogues. 
  
Reports submitted to the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA), user reports on websites and case reports
1
 indicate that 
routes of administration may include snorting, smoking/inhalation, injection, oral 
(ingestion), sub-lingual, rectal and mixed routes (oral and injection) of 
administration. Detailed information on common dosage levels may be difficult to 
obtain, especially if drug or product purities are not known, and it would appear that 
a particular route of administration might require varying dosage levels. Some 
tentative estimation pointed toward threshold levels around 1-2 mg to "strong" 
effects between 20-25 mg by oral ingestion. Nasal insufflation might result in more 
potent effects.
59
 Dosage levels associated with α-PVP appear to be relatively similar 
to those reported for MDPV
60
 but this has to remain speculative.  
   
C. Pharmacokinetics 
Information collected from systematic studies in humans is lacking but some data 
became available in recent years grounded in in-vitro studies and observations made 
in casework. Results obtained from casework analyses indicated that metabolically 
unchanged α-PVP was detectable and that other transformation products may be 
equally relevant for targeted analyses, such as the reduced β-hydroxy (HO-PVP) 
species and a range of additional analytes associated with modifications at the 
pyrrolidine ring, phenyl ring and α-alkyl group. 
 
The first investigation published in 2009 was based on the implementation of a 
screening procedure in rat urine (male Wistar, α-PVP administration by gastric 
intubation, 20 mg/kg and 1 mg/kg) following analysis by gas chromatography mass 
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spectrometry and chemical derivatization.
14
 A range of biotransformation products 
were detected and included PVP, N,N-bis-dealkyl-PVP, the pyrrolidin-2-one 
derivative 2’’-oxo-PVP, hydroxyalkyl-PVP, hydroxyphenyl-N,N-bis-dealkyl-PVP, 
hydroxyphenyl-PVP, hydroxyalkyl-2’’-oxo-PVP, carboxy-4-oxo-PVP, hydroxy- 
phenyl-2’’-oxo-PVP, di-hydroxy-PVP, hydroxyphenyl-carboxy-4-oxo-PVP, and 
hydroxyphenyl-carboxy-4-oxo-PVP. Side chain hydroxylation of α-PVP appeared 
to be catalyzed following exposure to human hepatic cytochrome-P450 (CYP) 
enzymes CYP2B6, CYP2C19, CYP2D6, and CYP1A2, respectively.
14,61
 More 
recently, seven Phase I metabolites were identified in authentic human urine 
samples which confirmed a number of transformation steps such as reduction, 
hydroxylation, hydroxylation + dehydrogenation, reduction + hydroxylation + 
dehydrogenation, degradation of pyrrolidine ring, hydroxylation + dehydrogenation 
+ ring opening + oxidation, and hydroxylation + oxidation, respectively. The 
reduced ketone, i.e. giving rise to 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-ol (HO-
PVP), was found to be the most abundant species in the analyzed human urine 
samples and in samples derived from in vitro experiments with human liver 
microsomes.
29
 Similarly, the detection of the hydroxyalkyl-PVP species was also 
noted based on investigations in case work and in vitro studies.
45
 Analyses of urine 
samples obtained from a substance user who administered a drug mixture 
intravenously led investigators to estimate an urinary elimination half-live of 22 h 
for α-PVP based on the first five days of urinary analysis. Elimination half-live of 
α-PVP estimated for the second half period 6-10 days after injection was 40 h.35 
The analysis of authentic human urine samples also revealed the detection of HO-
PVP diastereomers, 2’’-oxo-PVP, 2’’-HO-PVP and HO-PVP glucuronide.37 A 
large-scale investigation of submitted urine samples confirmed the detection of the 
unchanged molecule, metabolites derived from pyrrolidine degradation and primary 
amine formation followed by reduction to alcohols. The suggestion was made that 
direct reduction to HO-PVP without pyrrolidine degradation may be less 
pronounced in PVP-type substances.
40
 A recent investigation into in vitro Phase I 
and Phase II metabolism of α-PVP revealed the detection of six Phase I and two 
glucuronidated metabolites. Phase I metabolites were formed following reduction, 
hydroxylation, and pyrrolidine ring transformation. The main metabolite formed 
under the investigated conditions was the reduced β-hydroxy-2’’-oxo-PVP species 
that was associated predominantly with recombinant human CYP2C19, CYP2B6 
and CYP2C9 activity as determined by separate in vitro studies.
47
  
5. Toxicology 
The LD50 of α-PVP hydrochloride (mouse, intravenous) was given at 38.5 mg/kg.
62
 A 
recently carried out cytolysis test that employed α-PVP and a variety of other pyrovalerone 
analogues did not lead to observations of cytotoxic effects under the conditions studied 
(after 4 h of incubation at 37°C, drug concentration 100 μM).53 Data on the effects of α-
PVP metabolites are currently not available.  
6. Adverse reactions in humans 
Tables 5-8 provide an overview of fatal and non-fatal intoxications obtained from the 
scientific literature and from reports received by the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA).
1
 Representative, clinically relevant observations 
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have been added where available. It is worth noting that α-PVP was not always the only 
substance present in the analyzed biofluids and this can pose challenges when attempting 
to disentangle causal relationships, especially in the absence of detailed pharmacokinetic 
data obtained from human studies. A causal link could not be established in all cases and 
other confounders such as pre-existing history of poly-drug use and mental health problems 
might have been relevant as well. In cases where α-PVP use was established 
unambiguously, neurological and cardiovascular effects consistent with an extensive 
psychostimulant toxidrome have been observed and included cardiotoxicity, violent 
behavior and display of psychotic behavior.    
 
Table 5. Fatal case reports associated with α-PVP published in the scientific literature 
Year Cases Patient, 
age 
Context/clinically related comments 
(examples) 
Notes Ref 
2013 1 M, 32 
 
Death (M, 32) following nasal insufflation;  
post-mortem: moderate obesity, pulmonary 
oedema, atherosclerotic heart disease with 
70% narrowing of the right coronary artery 
and fatty liver changes with fibrosis. 
 
 
Purchase of product “NRG-3” 
on Internet labelled with 
incorrect structure and 
chemical name; α-PVP 
confirmed by analysis; post-
mortem plasma and urine 
concentrations of α-PVP 1500 
ng/mL and 5 μg/mL; alcohol 
3.65 g/L, THC, THC-COOH 
and 11-HO-THC = 3.3, 14.2 
and 2 ng/mL.  
Eiden et al.
a,21
 
 
 
2013 6 2 x M, 
34 and 
51 
4 x F, 
32–50 
Review of post-mortem cases confirming 
α-PVP detection; all cases included 
multiple drug intoxications; deaths 
concluded to include accidents and 
homicide.   
Qualitative analyse of blood 
and urine samples. 
Marinetti and 
Antonides
23
 
2013 1 F, 35 Found unconscious and pronounced dead 
at hospital; signs of needle marks on left 
forearm and subcutaneous hemorrhage 
along left arm veins; multiple drug 
intoxication; presence of MDPV, α-PBP 
and α-PVP. 
MDPV (1,200 ng/mL) and α-
PBP (200 ng/mL) detected in 
cardiac blood; α-PVP detected 
in hair segments; range 0.2–
1.2 ng/10 mm.  
 
Namera et 
al.
25
 
2013 3 3 x M, 
31, 25, 
51 
Period March–May 2012; 51-yr case: 
found deceased on bathroom floor, powder 
residues within nostrils.  
31-yr case: “seizure activity” noted before 
death. 
 
25-yr case: firearm injuries and 
confrontation with law enforcement; 
aggressive, paranoid behaviour, and 
suicidal threats were mentioned. 
51-yr case, blood: α-PVP 0.1 
mg/L; THC and THC-COOH 
2.6 and 25 ng/mL. 
 
31-yr case, blood: α-PVP 0.52 
mg/L; sertraline (0.16 mg/L), 
oxycodone (0.02 mg/L), and 
7-aminoclonazepam (< 0.01 
mg/L) also detected. 
 
25-yr case, blood α-PVP 0.29 
mg/L and pentedrone 0.48 
mg/L. 
Richards-
Waugh et al.
63
 
2013 1 M, 32 Violent behavior preceding death in 
hospital; autopsy findings unremarkable; 
route of administration unknown; small 
glass bottle with liquid found in pocket.  
Whole blood from heart: α-
PVP 486 ng/mL; α-PVP 
present in liquid sample.  
Saito et al.
26
 
2013 14 Not 
specified 
Details not reported; various causes and 
manners of death; other substances always 
detected; most prevalent drug classes 
Post-mortem blood samples α-
PVP: 5-732 ng/mL (317 ± 227 
ng/mL)  
Shanks et al.
27
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included cannabinoids (n = 7), opioids (n = 
6), amphetamines (n = 5), and 
antidepressants (n = 4). Other substituted 
cathinones detected in 4 of the cases. 
2014 1 M, 41 Violent and agitated behaviour in 
apartment preceding death; no injuries 
related to death observed but external 
abrasions and subcutaneous hemorrhages; 
detection of caffeine, α-PVP and 
metabolite 1-phenyl-2-(pyrrolidin-1-
yl)pentan-1-ol (OH-α-PVP). 
Detection of α-PVP and OH-
α-PVP in various biofluids 
and solid tissues, e.g. femoral 
blood: 654 and 364 ng/mL; 
urine: 11.2 and 5.3 μg/mL; 
caffeine (100 ng/mL) in whole 
blood. 
Hasegawa et 
al.
31
 
2014 1 M, ‘in 
his 40s’ 
Violent and suicidal behaviour in “rented 
room” preceding death; cardiopulmonary 
arrest. 
Blood, right ventricle, left 
ventricle, and femoral vein; α-
PVP levels: 597, 635 and 580 
ng/mL. 
Minakata et 
al.
34
 
2014 1 M, ‘mid-
20s’ 
Sudden violent behaviour followed by 
sustained restraint for 2 hours by 
roommates; white powder found and 
confirmed to represent α-PVP; sudden 
death/cardiac arrest considered 
consequence of restraint and α-PVP 
intoxication. 
α-PVP serum levels 411 
ng/mL;  
Nagai et al. 
64
 
2014 1 M, 44 History of substance; injection with 
product obtained from shop called 
“Smokin’ Slurry Scrubba”; autonomic 
hyper-arousal, followed by cardiac arrest, 
rhabdomyolysis, renal failure, hepatic 
injury, anoxic brain injury 43 hours later 
and death. 
α-PVP detected in coronial 
blood ante-mortem and post-
mortem; qualitative analysis; 
immunoassay positive for 
benzodiazepines.   
Sellors et al.
65
 
2015 1 M, 28 History of “designer drugs” use; brought to 
hospital in asystole but died; white powder 
found labelled as “α-PVP”; autopsy 
revealed pulmonary oedema and 
moderately advanced atherosclerotic 
lesions of arteries. Chronic changes in the 
heart observed by microscopic 
observation.  
Detection of pentedrone, α-
PVP, OH-α-PVP in various 
biofluids and solid tissues, e.g. 
whole (femoral) blood: 8,794, 
901 and 185 ng/mL.  
Sykutera et 
al.
48
 
2015 1 M, 40 Single vehicle collision against tree with 
high speed; also detected in blood: ethanol 
(0.05 g/100 mL), MDMA (~ 0.06 mg/L), 
diazepam (~ 0.2 mg/L), nordiazepam (~ 
0.1 mg/L), oxycodone (~ 0.03 mg/L), 
paracetamol (trace), THC (~ 14 ng/mL). 
 
MDPV (~60 ng/ mL) and α-
PVP (~77 ng/ mL) detected in 
blood. 
Yap and 
Drummer
49
 
a
 Case also reported to the EMCDDA. 
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Table 6. Case-level data for death cases reported to European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA)
1
  
Member States (number of cases):  
 Finland (37), France (2), Hungary (19), Ireland (5), Poland (21), Sweden (16) and United Kingdom (6). 
Demographics: 
 Male: 81 (80.2%); female: 20 (19.8%)  
 Age (years): mean age of male decedents 36.3 (n = 66; median 33); mean age of female decedents 35.4 (n = 20; 
median 34.5). 
Number of deaths by year: 
 2012 (17); 2013 (24); 2014 (43); 2015 (Jan–July, 15)  
Information about cause of death (preliminary review reported for 101 deaths): 
 α-PVP reported as the cause of death (3 cases) or as contributing factor (20). 
 Not known; investigations ongoing in some cases (26). 
 Cause of death reported as due to drug intoxication, no further details available (4). 
 Further investigation needed to confirm the role of α-PVP played in the deaths, if any (48).  
 
Table 7. Non-fatal case reports associated with detection of α-PVP reported in the scientific literature 
Year Cases Patient, 
age 
Context/clinically related comments 
(examples) 
Notes Ref 
2013 1 M, 27 Non-fatal (M, 27): admission to emergency 
department following nasal insufflation: heart 
rate was 128 betas/min, blood pressure 160/90 
mmHg, respiratory rate 30 breaths/min, oxygen 
saturation 97% and temperature 37.1°C, 
bilateral mydriasis; pertinent initial laboratory 
data indicated rhabdomyolysis without renal 
failure: creatine kinase 1841 IU/L, myoglobin 
275 μg/L, C-reactive protein 33.5 mg/L and 
normal lactic acid. Hepatic and pancreatic 
parameters normal; patient confirmed 
occasional consumption of NRG-3 (a few days 
every 2 months for 6 months) by nasal route, 
also cannabis and alcohol. Twelve hours after 
last NRG3 intake (10 h after emergency 
admission), visual hallucinations were 
mentioned. Diazepam (20 mg, i.v.) and 
olanzapine (20 mg, i.v.) given to treat persistent 
anxiety, agitation, temporo-spatial disorientation 
and distorted perceptions. Urine positive for 
cannabis. 
Non-fatal case: purchase 
of product “NRG3” on 
Internet; α-PVP plasma 
235 ng/mL; urine > 5 
μg/mL; THC positive 
Eiden et al.
21
 
 
2013 4 Not 
reported 
Clinical features in four cases related to 
substance use not reported; analytical method 
applied to analysis of hair. Case 1: hair collected 
one month after most recent use; drug was 
injected several times with the aim to commit 
suicide.  
Case 2: patient was arrested and hospitalized.  
Case 3: Concentrations of α-PVP, α-PBP and 
MDPV decreased in hair segments > 20mm 
from the scalp; hair was dyed brown 20-30 mm 
from scalp; significant differences noted in 
MDPV and α-PVP concentrations between 
bleached and unbleached hair segments. 
Case 4: Patient consulted hospital. 
Case 1: α-PVP (9.4 
ng/mg) and α-PBP (3.1 
ng/mg) detected 10-30 
mm from scalp (2
nd
 
segment); 7.5 and 3.1 
ng/mg in 3
rd
 segment. 
Case 2:  α-PVP detected 
10-30 mm and 40-90 mm 
from scalp, e.g. 40+ 
ng/mg and ~50 ng/m in 
segments 2 and 3.  
Case 3: α-PVP (320+ 
ng/mg), MDPV (300+ 
ng/mg) detected in first 
segment; α-PVP, α-PBP 
and MDPV detected in 
Namera et 
al.
24
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segment 2.  
Case 4: α-PVP detected 
(4.5+ ng/mg) in pubic 
hair in segments 2 and 3 
(20-40 mm from skin).  
2014 1 M, 46 Admission to emergency department (in 2013) 
following ingestion of zolpidem with suicidal 
intent; no recorded history of psychiatric 
disorders but active chronic hepatitis C and 
Gilbert’s syndrome. Patient’s condition 
diagnosed as persistent substance-induced 
psychosis, secondary to prolonged intake of 
MDPV, mephedrone, butylone and α-PVP. 
Continuous use (from one to three times a 
week) of a non-specified recreational drug since 
July 2012 was mentioned. Powdered material 
analysed to confirm the four substances. 
Haloperidol decanoate (150 mg) administered 
every 4 weeks. Slight improvement noted about 
persecutory delusion but no change in insight. 
Traces of MDPV 
detected in urine.  
Dragogna et 
al.
66
 
2014 1 M, 34 Impaired driving and evaluation by drug 
recognition expert. Poor navigation observed; 
driver appeared confused, disoriented and 
agitated at times; involuntary muscle 
movements at various times; dilated pupils, 
elevated systolic blood pressure (150/82 
mmHg).   
Blood analysis: α-PVP 
(63 ng/mL) and 
methylone (6.1 ng/mL); 
positive for ethylone.  
Knoy et al.
32
 
2014 1 M, ‘in 
his 40s’ 
No clinical features reported. Several 
intravenous injections of “unregulated drug” 
with intention to commit suicide and admission 
to hospital several hours afterwards. Urine was 
collected for analysis each morning for one 
month. Based on first five days of urinary 
analysis (below LOD on day 10): urinary 
elimination half-lives 22 h and 11 h for α-PVP 
and α-PBP; elimination half-lives during second 
half period (6-10 days after injection) were 40 h 
and 30 h for α-PVP and α-PBP. 
Detection of α-PVP and 
α-PBP, plus their 
pyrrolidin-2-one-type 
metabolites. Highest 
concentration in first 
sample > 32 h after final 
injection: α-PVP 1.2 and 
and α-PBP 1.6 μg/mL.  
Namera et 
al.
35
 
2014 19 Not 
reported 
No clinical features reported. Urine sample 
obtained from 19 substance users. 
 Shima et al.
37
 
2014 8 Not 
reported 
No details reported. Urine samples collected at 
autopsy or represented clinical toxicology cases.  
α-PVP urine levels 0.08–
13 mg/L but other 
substances (not 
specified) were also 
detected.  
Tyrkkö et al. 
29
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Table 8. Non-fatal, case-level data reported to European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
1
  
Member States (number of cases):  
 France (10 cases), Germany (2), Ireland (5), Italy (1), Poland (1) and Sweden (15). Thirty-two of the 34 cases classified 
as non-fatal intoxications; in the remaining 2 cases the outcome of the intoxication was unknown (Germany, 1 case; 
Sweden, 1 case). 
 Analytical confirmation was obtained from 21 of the 34 cases: France (4), Italy (1), Poland (1), Sweden (15) and further 
information from the remaining 13 cases were unavailable.   
Demographics (21 analytically confirmed cases): 
 Male: 19 (90.5%); female: 2 (9.5%)  
 Age (years): mean age of male cases 33.2 (n = 18; median 28.5); mean age of female cases: 23 and 25 years (n = 
2). 
Substance identification (21 analytically confirmed cases): 
Sweden: 
 α-PVP was only substance identified (8 cases, biological matrices unknown). 
 α-PVP and ethanol were the only substances identified (5 cases, biological matrices not reported). 
 α-PVP and benzodiazepines (and metabolites of benzodiazepines) were the only substances identified (1 case, 
biological matrices not reported). 
 α-PVP and benzodiazepines (and metabolites of benzodiazepines) and ethanol were the only substances identified 
(biological matrices not reported). 
France: 
 α-PVP was only substance identified in blood; urine drug screening identified ‘cannabis’ (1 case). 
 In 1 case, it was not known if any other substances besides α-PVP were identified (biological matrices not 
reported). 
 α-PVP was only substance identified (2 cases, biological matrices not reported). 
Italy: 
 α-PVP and THC were analytically identified in urine (1 case). 
Poland: 
 α-PVP only substance identified in blood; pentedrone and alcohol were identified in urine (1 case).  
Seriousness of the intoxications (21 analytically confirmed acute intoxications): 
 Seriousness of intoxication classified as life threatening, requiring treatment in hospital: 5 cases (in 3 cases α-PVP 
was only substance identified; in 1 case α-PVP and benzodiazepines (and metabolites of benzodiazepines) were the 
only substances identified; in 1 case α-PVP and benzodiazepines (and metabolites of benzodiazepines) and ethanol 
were the only substances identified). 
 Seriousness of intoxication classified as non-life threatening but required treatment in hospital: 11 cases (in 1 case, 
seriousness of intoxication was classified as involving persistent or significant disability or incapacity; in 2 cases 
seriousness of intoxication was classified as ‘moderate’ using an alternate, national, classification system 
(‘moderate’ is synonymous with pronounced or prolonged symptoms or signs). 
 Seriousness of intoxication not reported (2 cases). 
Outcome of the non-fatal intoxications. Of the 20 analytically confirmed non-fatal intoxications: 
 Outcome classified as recovered/resolved in 12 cases. 
 Outcome classified as recovering/resolving in 2 cases. 
 Outcome classified as not known in 4 cases. 
 Outcome not reported in 2 cases.  
EMCDDA definition:  
Serious adverse event means any adverse event, whether analytically confirmed or not, that is associated with the 
consumption of a new psychoactive substance in a human that: results in death; is life-threatening; requires intensive 
treatment in an emergency room and/or requires hospitalization; results in persistent or significant disability or incapacity; 
results in substance dependency or substance abuse; consists of a congenital anomaly or birth defect; or is an important 
medical event that may not be immediately life-threatening or result in death or hospitalization but may jeopardize 
the patient or may require intervention to prevent one of the other outcomes listed above. Examples of such events 
are: convulsions that do not result in hospitalization. 
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7. Dependence potential 
A. Animal Studies 
An overview of animal studies carried out with α-PVP and representative data is 
summarized in Table 3 and Section 4A. The behavioral effects induced by α-PVP 
were observed to be comparable to other psychomotor stimulants such as cocaine, 
methamphetamine and MDPV but further studies are warranted to assess 
dependence potential in animals in more detail. 
B. Human Studies 
Data on systematic clinical studies in humans are currently not available.  
8. Abuse potential 
A. Animal Studies 
As shown in Table 3 and Section 4A, the comparison with other psychomotor 
stimulants, such as cocaine, methamphetamine and MDPV, indicated that α-PVP 
displayed comparable potential for abuse under the conditions studied.  
 
B. Human Studies 
Data on systematic clinical studies in humans are currently not available.  
9. Therapeutic applications and extent of therapeutic use and epidemiology 
of medical use 
Not applicable. 
10. Listing on the WHO Model List of Essential Medicines 
α-PVP is not listed.  
11. Marketing authorizations (as a medicinal product) 
α-PVP was never marketed as a medicinal product.   
12. Industrial use 
α-PVP has no recorded industrial use.  
13. Non-medical use, abuse and dependence  
As shown in previous sections, use of α-PVP appears to be limited to recreational 
substance users and attendees of drug treatment centers rather than the general population. 
The mode of use may involve the combinational use (intentionally or unintentionally) of 
other drugs and users may be unaware of the exact dose or compound being ingested (by 
whatever route). Dependence-producing properties in humans have not been studied.   
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14. Nature and magnitude of public health problems related to misuse, abuse 
and dependence 
Information obtained from sources described in earlier sections indicates that α-PVP 
appears to be associated with the purchase of ‘research chemicals’ or comparable products 
that may be obtained from Internet retailers. It has also been observed that α-PVP was 
encountered in tablets and related formulations sold as ‘ecstasy’ both in Europe and the 
Americas.
1, 67
 It also appears that α-PVP is used by recreational and high-risk drug users, 
including those who inject drugs.
1, 68, 69
 Surveys that systematically assess the prevalence 
of use are currently not available. Data from the Polish ‘I-Trend’ online questionnaire 
provided to the EMCDDA showed that out of 1074 respondents, α-PVP was the last new 
psychoactive substance to be used by 3.4% (n = 36) of the respondents (36 users, n = 
1,074). Of these, 39% had taken it at least 20 times in the previous year.
1
  
15. Licit production, consumption and international trade 
In countries where α-PVP is not subject to legislative control, marketing efforts might 
include advertisement and sale as ‘research chemical’, ‘bath salt’, ‘stain remover’, ‘plant 
food’, ‘plant fertilizer’, ‘insect repellant’, and jewelry cleaner’. Information about 
agricultural, cosmetic or industrial use of α-PVP is not available. A structured search of 
online vendors of α-PVP carried out by the EMCDDA (surface web, using three search 
strings: ‘buy a-PVP’, ‘buy alpha-PVP’ and ‘buy pyrrolidinopentiophenone’ on 
www.google.co.uk) identified 65 vendors that appeared to be based in, and/or claim to 
have presence in, the European Union (n = 28 sites), United States (n = 13 sites), China (n 
= 32 sites), India (n = 3 sites), or Russia (n = 6 sites).
1
  
16. Illicit manufacture and traffic and related information 
Information provided to Europol and EMCDDA by 28 European Member States, Turkey 
and Norway is summarized in Table 9. Four EU Member States (Hungary, Latvia, 
Romania and Spain) provided information in relation to the involvement of organized 
crime in the manufacture or trafficking of α-PVP. For the period of January 2010 through 
to December 2013, the System to Retrieve Information from Drug Evidence (STRIDE) 
logged 689 exhibits for α-PVP whereas 4,536 reports were registered by the National 
Forensic Laboratory Information System (NFLIS) between January 2010 and December 
2013.
70
 The NFLIS 2014 Midyear Report, covering total drug reports submitted to 
laboratories from 1
st
 January 2014 – 30th June 2014 (and analyzed by 30th September 
2014), provides a national estimate of 2,244 reports. In comparison, methamphetamine and 
MDMA numbers were 121,109 and 2,347, respectively.
71
 A number of 40 encounters were 
recorded by the United States Customs and Border Protection (CBP) between April 2010 
and November 2013.
70
  
 
  
37
th
 ECDD (2015) Agenda item 5.3    α-PVP 
 
 
 
 
Page 25 of 32 
Table 9. Information provided to Europol and European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) on 
seizures, levels of trafficking and manufacturing
 a,1
 
Information provided to Europol 
Seizures  
 First seizure reported in 2012. 
 Over 295 seizures in powder or crystalline powder form totalling over 370 kg of α-PVP. Most of the seizures were 
described as white or off-white in colour, but in one case from Spain the powder was described as ‘black rock 
powder’. 
 Three Member States reported seizures of tablets containing α-PVP: Czech Republic (160 tablets), Hungary (454 
tablets), Romania (2 tablets). Packages containing α-PVP were seized in Slovakia and in Spain. In 2015, Spain also 
reported a case with 2 jelly gums containing α-PVP.  
Level of trafficking 
 In one case, Poland was indicated as a country of origin and in the remaining 10 of the 11 cases (where trafficking 
route information was provided), China was noted as the source country for α-PVP. Mail shipments and courier 
services have also been reported to serve as routes for importation. Germany and France appear to serve as transit 
points in the EU and a large seizure from Spain (259 kg) indicates that this country might also serves as a 
distribution point. 
Level of production 
 Two tableting sites were encountered and dismantled in Hungary in 2013 and 2014. α-PVP was found in powdered 
form and suspected to be employed for tablet production. 
 Two α-PVP production sites were seized in Poland in 2013 and 2014. Approximately 50 kg of α-PVP were 
produced in this site and destined both for the domestic market and to be exported. According to the Polish 
authorities, both cases were linked to a local group of ‘football hooligans’. The synthesis was supervised by trained 
chemists, and the laboratories were operated by suppliers, producers and distributors of chemicals. The companies 
involved operated their own websites offering the sale and distribution of those substances across Poland. 
Information provided to EMCDDA 
Seizures 
 First seizure reported in 2011 (France).  
 α-PVP has been detected in more than 5200 seizures with eight countries reporting more than 100 seizures each: 
United Kingdom (1094), Poland (938), Finland (787), Slovakia (502), Sweden (451), Ireland (336), Hungary (313) 
and Turkey (256). 
 α-PVP was commonly seized in powder form with total amount of powder over 750 kg. Seven countries reported 
seizures over 10 kg: Spain (312 kg), Netherlands (140), France (81), Ireland (63), United Kingdom (62), Hungary 
and Finland (24 each) and Poland (17).  
 Thirteen countries reported seizures of tablets (Slovakia, Hungary, Finland, Czech Republic, Latvia, Turkey, 
Sweden, Norway, Spain, Poland, Belgium, Italy and France) amounting to over 12400 units. Of those, three 
countries reported seizures of over 1000 tablets: Slovakia (7157), Hungary (3768) and Finland (1136). The United 
Kingdom reported three seizures of powder-filled capsules. 
 Seven countries (Lithuania, the United Kingdom, Hungary, Slovakia, France, Sweden and Poland) reported small 
seizures (< 150 grams) of vegetable material containing α-PVP, occasionally also containing synthetic 
cannabinoids.  
 Three countries (Finland, Sweden and Poland) have seized small quantities of liquid (< 150 mL) containing α-PVP.  
 Austria reported a single seizure of 68 paper doses (also known as a ‘blotters’) containing 2,5-dimethoxy-4-
chloroamphetamine (DOC) and α-PVP. Finland reported 16 seizures amounting to over 700 units of 
tablets/blotters. Spain reported the seizure of 2 jelly gums, where α-PVP, amphetamine and caffeine were detected. 
 In around 35% of the detections, α-PVP was found in combination with other substances including other synthetic 
ring-substituted cathinones, synthetic cannabinoids and a range of other new psychoactive substances. A number of 
them are internationally controlled and/or controlled at EU-level. Substances typically used as cutting agents and/or 
diluents included benzocaine, lidocaine and caffeine.  Information on purity, which was available from 16 seizures, 
ranged from 23% (2 seizures) to over 95 % (8 seizures). 
 Tablets containing α-PVP had the following markings: ‘Lacoste’, ‘Playboy’, ‘STADA1’ and ‘Homer Simpson’ 
(information available for 7 seizures) which suggested that α-PVP might have been sold as ’ecstasy’. Unmarked 
tablets in a variety of colors have been reported. Some of these products were obtained through online shops. 
 Eleven countries reported fifty samples collected from users or purchased on the Internet, which contained α-PVP 
(Austria, Belgium, Czech Republic, Denmark, France, Hungary, the Netherlands, Slovenia, Spain, Turkey and the 
United Kingdom).  
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Level of production 
 The Reitox National Focal Point from the Slovak Republic reported the dismantling of a manufacturing and 
distribution site linked to new psychoactive substances intended to be marketed in Slovakia and Hungary. Fifteen 
kilograms of new psychoactive substances (3-methylmethcathinone, α-PVP and methiopropamine) were seized. 
The ingredients necessary for the production of these substances were imported from Hungary and, following their 
processing in Slovakia, were to be re- exported back to Hungary.
72
 
a
 Some of the data reported to Europol and EMCDDA may overlap. Many ‘seizures’ related to individual case-level data, 
however, some data provided to the EMCDDA were aggregated at the country level. Some of the data from the United 
Kingdom were reported as ‘records’, where several records may come from the same case. Data were drawn from the Joint 
Report Questionnaires and data provided in the bi-annual data gathering (EU EWS progress and final reports) and from 
individual Reporting forms submitted on an ad hoc basis. 
17. Current international controls and their impact 
Not applicable in terms of medical use. 
18. Current and past national controls 
The EMCDDA has received confirmation from fifteen Member States (Estonia, Finland, 
France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Poland, Romania, 
Slovenia, Sweden and the United Kingdom) as well as Turkey and Norway and reported 
that α-PVP is controlled under drug control legislation:1 
a. Estonia: listed in the Regulation No. 73 of the Minister of Social Affairs of 18 May 
2005 since 2 June 2014. 
b. Finland: listed in the Narcotics Act 373 of 2008 since 30 December 2013. 
c. France: added to the controlled narcotic substance list since 2 August 2012. 
d. Germany: placed under schedule II (narcotics eligible for trade but not for medical 
prescription) of the Narcotic Substance Act, effective as of 17 July 2013. 
e. Greece:  considered to be controlled under law 3459/2006 due to same molecular 
weight and molecular formula as metazocine, an opioid analgesic classified in 
Table C of this law. 
f. Hungary: listed in Schedule A (psychotropic substances) of Act XXV of 1998 on 
human pharmaceuticals since 1 January 2015. 
g. Ireland: covered by generic definition of controlled cathinones included in the 
Misuse of Drugs Act. 
h. Italy: covered by generic definition under the Decree of the President of the 
Republic 309/90 since 29 December 2011. 
i. Latvia: controlled generically according to Cabinet Regulation 847 ‘Regulations 
regarding narcotic substances, psychotropic substances and precursors to be 
controlled in Latvia’. 
j. Lithuania: controlled as a cathinone derivative by an Amendment to the Law on the 
control of narcotic drugs and psychotropic substances adopted in 2010. 
k. Poland: listed in Schedule IV of the Act of 24 June 2015 amending the Act of 
Counteracting Drug Addiction since 1 July 2015. 
l. Romania: controlled by Law 143/2000 on preventing and combating trafficking and 
illicit drug use and listed in Table I of the law 339/2005 on the legal regime of 
plants, narcotic and psychotropic substances and preparations. 
m. Slovenia: included by the Decree on amending the Decree on Classification of 
Illicit Drugs, Official Gazette of RS No. 45/2014 since July 2014. 
n. Sweden: captured by the Narcotic Drugs Control Act since 1 February 2013. 
37
th
 ECDD (2015) Agenda item 5.3    α-PVP 
 
 
 
 
Page 27 of 32 
o. United Kingdom: captured by generic definition of substituted cathinone 
derivatives placed under the Misuse of Drugs Act 1971 in April 2010 and it is 
controlled as a class B drug. 
p. Turkey: listed in the Law on Control of Narcotics No.2313 adopted on 22 March 
2012. 
q. Norway: covered by generic definition of cathinones in the Norwegian list of 
narcotics. 
 
Four Member States (Austria, Cyprus, Portugal and Slovakia) reported that α-PVP is 
controlled under legislation prohibiting the unauthorized supply of defined or qualifying 
new psychoactive substances.  
a. Austria: categorized as member of the ‘amino phenyl ethanone’ (i.e. cathinone) 
generic group in the New Psychoactive Substances Act. 
b. Cyprus: captured by generic definition of a cathinone under specific NPS 
legislation as of 24 June 2011. 
c. Portugal: listed as controlled under Decree-Law 154/2013 of 17 April 2013. 
d. Slovakia: listed as a ‘hazardous substance’ as of 1 October 2013. 
 
The EMCDDA received reports that Belgium and Czech Republic started the process of 
controlling the substance using drug control legislation.  
 
In the United States of America, α-PVP has been temporarily scheduled into schedule I 
pursuant to the temporary scheduling provisions of the Controlled Substances Act (CSA).
70
 
Other countries with legislative control include Japan (“Designated Substance”) and other 
United Nation Member States.  
19. Other medical and scientific matters relevant for a recommendation on 
the scheduling of the substance 
 
Not applicable. 
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